IMpower150：EGFR 突变亚组中的 Atezolizumab + Bevacizumab + 化疗信号
类型: III期临床试验亚组 / 免疫治疗 + 抗血管 发表日期: 2021-10-07 入库日期: 2026-05-21 来源: PubMed / Journal of Thoracic Oncology 标签: EGFR L858R, IMpower150, Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel, 免疫治疗, 抗血管
Citation
Reck M, et al. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. Journal of Thoracic Oncology. 2022. PMID: 34626838. DOI: 10.1016/j.jtho.2021.09.014
Related final overall survival report: Socinski MA, et al. IMpower150 Final Overall Survival Analyses. Journal of Thoracic Oncology. 2021. PMID: 34311108.
Why it matters for mom
IMpower150 is older and not designed solely for EGFR-mutant post-osimertinib disease, but it is a foundational signal behind later trials that combine PD-L1 blockade, bevacizumab, and chemotherapy in oncogene-driven NSCLC.
It matters because doctors may mention the "ABCP" concept: atezolizumab + bevacizumab + carboplatin + paclitaxel.
Practical takeaways
- Treat IMpower150 as hypothesis-supporting and regimen-context evidence, not as a clean one-to-one match to mom's current course.
- It supports why anti-VEGF may matter when immunotherapy is used in EGFR-mutant NSCLC.
- Paclitaxel/carboplatin toxicity differs from pemetrexed/platinum toxicity; marrow reserve and neuropathy matter.
- Later EGFR-specific trials such as ORIENT-31 and ATTLAS are more directly relevant to the post-TKI setting.
Questions for doctors
- If ABCP is proposed, why this regimen instead of pemetrexed-based chemotherapy, amivantamab-chemo, ADC trial, or molecularly targeted resistance therapy?
- What are the expected benefits in EGFR L858R specifically, and what toxicities are most limiting for her current condition?
- Is anti-VEGF safe given bone/sternum disease, procedure plans, and blood counts?